0001932393-25-000014 | 10-Q | XBRL Viewer | GE Healthcare Technologies INC

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.


	As of
	March 31, 2025		December 31, 2024
Cash and cash equivalents	$	2,454	$	2,874
Short-term restricted cash	19		16
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position	2,473		2,889
Long-term restricted cash(1)	3		3
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows	$	2,476	$	2,893

(1) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

Schedule of Restricted Cash and Cash Equivalents

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.


	As of
	March 31, 2025		December 31, 2024
Cash and cash equivalents	$	2,454	$	2,874
Short-term restricted cash	19		16
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position	2,473		2,889
Long-term restricted cash(1)	3		3
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows	$	2,476	$	2,893

(1) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

Schedule of Inventory

INVENTORIES.


	As of
	March 31, 2025		December 31, 2024
Raw materials	$	991	$	921
Work in process	99		92
Finished goods	1,068		926
Inventories	$	2,158	$	1,939

Summary of Property, Plant and Equipment

PROPERTY, PLANT, AND EQUIPMENT – NET.


	As of
	March 31, 2025		December 31, 2024
Land and improvements	$	146	$	66
Buildings, structures, and related equipment	2,107		1,943
Machinery and equipment	2,905		2,705
Leasehold improvements and manufacturing plants under construction	503		553
Total property, plant, and equipment, at original cost	5,661		5,267
Accumulated depreciation	(3,179)		(3,080)
Right-of-use operating lease assets, net of amortization	369		364
Property, plant, and equipment – net	$	2,851	$	2,550

Schedule of Other Current Assets


All Other Current Assets	As of
	March 31, 2025		December 31, 2024
Prepaid expenses and deferred costs	$	249	$	188
Financing receivables – net	90		90
Derivative instruments(1)	100		123
Tax receivables	116		115
Other(2)	46		16
All other current assets	$	601	$	532

(1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information.

(2) Current assets Other primarily represents indemnity assets associated with separation agreements with GE as of March 31, 2025.

Schedule of Other Noncurrent Assets


All Other Non-Current Assets	As of
	March 31, 2025		December 31, 2024
Prepaid pension asset	$	723	$	657
Equity method and other investments	235		373
Financing receivables – net	186		183
Long-term receivables – net	161		142
Inventories	143		139
Contract and other deferred assets	213		208
Capitalized cloud computing arrangement implementation costs	113		84
Other(3)	152		164
All other non-current assets	$	1,926	$	1,950

(3) Non-current assets Other primarily consists of indemnity assets associated with separation agreements with GE, derivative instruments, and tax receivables.

Schedule of Other Current Liabilities


All Other Current Liabilities	As of
	March 31, 2025		December 31, 2024
Sales allowances and related liabilities	$	221	$	242
Income and indirect tax liabilities including uncertain tax positions	286		279
Product warranties	171		168
Accrued freight and utilities	154		163
Operating lease liabilities	119		115
Derivative instruments(1)	120		90
Interest payable on borrowings	141		92
Environmental and asset retirement obligations	17		17
Other(4)	355		386
All other current liabilities	$	1,583	$	1,552

(1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information.

(4) Current liabilities Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and dividends payable to stockholders.

Schedule of Other Noncurrent Liabilities


All Other Non-Current Liabilities	As of
	March 31, 2025		December 31, 2024
Contract liabilities	$	724	$	686
Operating lease liabilities	266		270
Environmental and asset retirement obligations	395		291
Income and indirect tax liabilities including uncertain tax positions	170		237
Derivative instruments(1)	39		64
Finance lease obligations	40		40
Sales allowances and related liabilities	24		23
Other(5)	182		184
All other non-current liabilities	$	1,840	$	1,796

(1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information.

(5) Non-current liabilities Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.

Schedule of Redeemable Noncontrolling Interest

Activity attributable to redeemable noncontrolling interests is presented below.


	For the three months ended March 31
	2025		2024
Balance at beginning of period	$	188	$	165
Net income attributable to redeemable noncontrolling interests	24		11


Balance at end of period	$	211	$	177

Schedule of Other Income (Expense)

OTHER INCOME (EXPENSE) – NET.


	For the three months ended March 31
		2025		2024
Net financing income and investment income (loss)		$	(1)	$	(16)
Equity method income (loss)		3		1
Change in fair value of assumed obligations		(8)		(8)
Gain on remeasurement of NMP equity method investment(1)		97		—
Other items, net(2)		8		14
Total other income (expense) – net		$	99	$	(8)

(1) Refer to Note 7, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

(2) Other items, net primarily consists of licensing and royalty income, lease income, change in tax indemnities, and gains and losses related to derivatives. Additionally, for the three months ended March 31, 2025 it includes a realization of a gain contingency.

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

Changes in Accumulated other comprehensive income (loss) - net by component were as follows.


	For the three months ended March 31, 2025
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2024	$	(1,973)	$	576	$	18	$	(1,379)
Other comprehensive income (loss) before reclassifications – net of taxes of $15, $5, and $3	194		(20)		(11)		163
Reclassifications from AOCI – net of taxes(2)(3) of $—, $16, and $—	63		(49)		3		17
Other comprehensive income (loss)	257		(69)		(8)		180
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
March 31, 2025	$	(1,717)	$	507	$	10	$	(1,199)


	For the three months ended March 31, 2024
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2023	$	(1,706)	$	1,033	$	(18)	$	(691)
Other comprehensive income (loss) before reclassifications – net of taxes of $(7), $(1), and $(4)	(76)		2		15		(58)
Reclassifications from AOCI – net of taxes(2) of $—, $12, and $—	—		(38)		—		(37)
Other comprehensive income (loss)	(76)		(35)		16		(95)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
March 31, 2024	$	(1,781)	$	997	$	(2)	$	(787)

(1) The amount of Currency translation adjustments recognized in Other comprehensive income (loss) (“OCI”) during the three months ended March 31, 2025 and 2024 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”

(2) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Condensed Consolidated Statements of Income.

(3) Includes net of tax impact of $63 million to Currency translation adjustments and $8 million to Pension and Other Postretirement Plans related to the derecognition of the prior NMP equity method investment. Refer to Note 7, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Effect of Derivatives Instruments on Statements of Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	$ 0	$ 0
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	(3)	5
SG&A \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of derivatives not designated as hedging instruments	0	0
SG&A \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
SG&A \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
SG&A \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
SG&A \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
SG&A \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	(3)	5
Interest and other financial charges – net
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of net investment hedges	11	10
Effects of fair value hedges	(4)	(6)
Effects of derivatives not designated as hedging instruments	0	0
Interest and other financial charges – net \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of derivatives not designated as hedging instruments	0	0
Interest and other financial charges – net \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	8	8
Interest and other financial charges – net \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	3	2
Interest and other financial charges – net \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	57	(45)
Interest and other financial charges – net \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(61)	38
Interest and other financial charges – net \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0
Other
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	(15)	20
Other \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of derivatives not designated as hedging instruments	(1)	0
Other \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Other \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Other \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Other \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Other \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	(15)	20
Interest expense \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(4)	(6)
Product \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(2)	(1)
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	15	(12)
Product \| Cost of revenue \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(2)	(1)
Effects of derivatives not designated as hedging instruments	15	(12)
Product \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Product \| Cost of revenue \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Product \| Cost of revenue \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Product \| Cost of revenue \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Product \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0
Service \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	0
Effects of net investment hedges	0	0
Effects of fair value hedges	0	0
Effects of derivatives not designated as hedging instruments	4	(3)
Service \| Cost of revenue \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	0
Effects of derivatives not designated as hedging instruments	4	(3)
Service \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Service \| Cost of revenue \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Service \| Cost of revenue \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Service \| Cost of revenue \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0
Service \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	$ 0	$ 0

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

Nihon Medi-Physics

On March 31, 2025, the Company acquired the remaining 50% interest in Nihon Medi-Physics Co., Ltd (“NMP”) from joint venture partner Sumitomo Chemical for net cash consideration of $269 million. The acquisition was funded with cash on hand. NMP is a leading pharmaceutical manufacturer in Japan, focused on radiopharmaceuticals, which are used to enable clinical images across neurology, cardiology, and oncology procedures, as well as nonclinical and clinical development of radiotracers and theranostics research. Their product portfolio includes several GE HealthCare radiopharmaceuticals. NMP is included in the Company’s PDx segment.

On March 31, 2025, the fair value of the Company’s existing 50% interest in NMP was determined to be $301 million based on the cash consideration exchanged for acquiring the remaining 50% equity interest. The carrying value of our 50% interest was $204 million. The Company recognized a net gain of $97 million resulting from this remeasurement to fair value. This gain included the reclassification of certain amounts related to the Company’s 50% interest out of Accumulated other comprehensive income (loss) – net (“AOCI”) including foreign currency translation gains of $63 million and losses related to a defined benefit pension plan of $8 million. The net gain from this remeasurement was recorded in Other (income) expense – net in the Company’s Condensed Consolidated Statements of Income for the three months ended March 31, 2025.

The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.


	Purchase consideration
Cash consideration, net of cash acquired	$	269
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	$	575

The estimated fair values of the assets and liabilities assumed in connection with the acquisition of NMP are as follows.


	Initial allocation
Receivables	$	53
Inventories	10
Property, plant, and equipment	243
Goodwill	216
Other intangible assets	223
All other non-current assets(1)	52
Deferred income taxes	(87)
All other non-current liabilities	(107)
Other(2)	(28)
Total net assets post acquisition	$	575

(1) All other non-current assets includes $12 million of indemnification assets, with the underlying indemnified liabilities recorded in All other non-current liabilities.

(2) Other includes Accounts payable, All other current liabilities, and Current compensation and benefits.

The initial allocation of purchase price of NMP to the tangible and intangible assets acquired and liabilities assumed, as reflected in the table above, is based on the Company’s preliminary allocations of their fair values. The valuation of assets acquired and liabilities assumed has not yet been finalized as of March 31, 2025. While all amounts remain subject to adjustments, the areas subject to the most significant potential adjustments are property, plant, and equipment, intangible assets, decommissioning liabilities, and deferred income taxes. The preliminary valuation required estimates and assumptions including, but not limited to, estimating future cash flows and direct costs in addition to developing the appropriate discount rates. Accordingly, the purchase price adjustments are preliminary and are subject to further adjustments as additional information becomes available and as additional analyses are performed, and such further adjustments may be material. The Company’s management believes the fair values recognized for the assets acquired and the liabilities assumed are based on reasonable estimates and assumptions.

Property, plant, and equipment is mostly comprised of land, buildings, equipment (including machinery, furniture, and fixtures) and construction in process. The fair value of property, plant, and equipment was determined using a market participant approach.

Other intangibles relate to $200 million of definite-lived intangible assets and $23 million of acquired in-process research and development. Definite-lived intangible assets consist primarily of developed product market authorization rights and customer relationships. The acquired definite-lived intangibles are being amortized over a weighted-average estimated useful life of approximately 12 years. The estimated fair value of intangibles was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of cash flows an asset would generate over its useful life.

The goodwill associated with NMP, recorded within the PDx segment, is non-deductible for tax purposes and is attributed to expected synergies with NMP’s existing assets and workforce that are expected to allow the Company greater access and growth in the Japan market.

Included in All other non-current liabilities are asset retirement obligations and decommissioning liabilities of $96 million, which were assumed in the transaction.

NMP has a defined benefit pension plan which has pension assets of $73 million and pension liabilities of $34 million, a net asset of $39 million, which we acquired in the transaction and is included in All other non-current assets.

Deferred income tax liabilities include the expected U.S. federal, state, and foreign tax consequences associated with temporary differences between the preliminary fair values of the assets acquired and liabilities assumed and the respective tax basis.

Due to the proximity of the acquisition date to the end of the Company’s first quarter, the revenues and earnings of NMP are not significant to our consolidated results. If the acquisition of NMP had taken place as of the beginning of 2024, consolidated revenues and earnings would not have been significantly different than reported amounts.

MIM Software

On April 1, 2024, the Company acquired 100% of the stock of MIM Software Inc. (“MIM Software”) for approximately $259 million, net of cash acquired of $11 million, and potential contingent payments valued at $13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $283 million. The acquisition included up to $23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The final purchase price allocation resulted in goodwill of $189 million, customer-related intangible assets of $52 million, developed technology intangible assets of $48 million, net deferred tax liabilities of $13 million, and other net assets of $7 million. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide.

Revenue and earnings of MIM Software included in the Company’s financial statements since the acquisition date are not material to our consolidated revenue and earnings. If the acquisition of MIM Software had taken place as of the beginning of 2023, consolidated revenues and earnings would not have been significantly different from reported amounts.

GOODWILL.


	Imaging		AVS		PCS		PDx		Total



Balance at December 31, 2024	$	3,581	$	4,987	$	2,035	$	2,533	$	13,136

Acquisitions	—		—		—		216		216
Foreign currency exchange and other	5		12		2		1		20
Balance at March 31, 2025	$	3,587	$	4,999	$	2,037	$	2,750	$	13,373

We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date.

OTHER INTANGIBLE ASSETS.



	As of March 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	230	$	(26)	$	204	$	112	$	(24)	$	88
Patents and technology	2,668		(2,021)		647		2,593		(1,987)		606
Capitalized software	1,751		(1,479)		272		1,743		(1,437)		306
Trademarks and other	47		(29)		17		33		(29)		4
Total definite-lived assets	4,696		(3,555)		1,141		4,481		(3,477)		1,004
Indefinite-lived assets(1)	97		—		97		74		—		74
Total other intangible assets	$	4,793	$	(3,555)	$	1,238	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired in-process research and development prior to project completion and are not amortized.

Amortization expense was $70 million and $80 million for the three months ended March 31, 2025 and 2024, respectively.

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

Nihon Medi-Physics

The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.


	Purchase consideration
Cash consideration, net of cash acquired	$	269
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	$	575

The estimated fair values of the assets and liabilities assumed in connection with the acquisition of NMP are as follows.


	Initial allocation
Receivables	$	53
Inventories	10
Property, plant, and equipment	243
Goodwill	216
Other intangible assets	223
All other non-current assets(1)	52
Deferred income taxes	(87)
All other non-current liabilities	(107)
Other(2)	(28)
Total net assets post acquisition	$	575

(1) All other non-current assets includes $12 million of indemnification assets, with the underlying indemnified liabilities recorded in All other non-current liabilities.

Included in All other non-current liabilities are asset retirement obligations and decommissioning liabilities of $96 million, which were assumed in the transaction.

MIM Software

GOODWILL.


	Imaging		AVS		PCS		PDx		Total



Balance at December 31, 2024	$	3,581	$	4,987	$	2,035	$	2,533	$	13,136

Acquisitions	—		—		—		216		216
Foreign currency exchange and other	5		12		2		1		20
Balance at March 31, 2025	$	3,587	$	4,999	$	2,037	$	2,750	$	13,373

OTHER INTANGIBLE ASSETS.



	As of March 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	230	$	(26)	$	204	$	112	$	(24)	$	88
Patents and technology	2,668		(2,021)		647		2,593		(1,987)		606
Capitalized software	1,751		(1,479)		272		1,743		(1,437)		306
Trademarks and other	47		(29)		17		33		(29)		4
Total definite-lived assets	4,696		(3,555)		1,141		4,481		(3,477)		1,004
Indefinite-lived assets(1)	97		—		97		74		—		74
Total other intangible assets	$	4,793	$	(3,555)	$	1,238	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired in-process research and development prior to project completion and are not amortized.

Amortization expense was $70 million and $80 million for the three months ended March 31, 2025 and 2024, respectively.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivative contracts is to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, equity prices, and commodity prices. These derivative contracts reduce, but do not entirely eliminate, the aforementioned risks. Our policy is to use derivative contracts solely for managing risks and not for speculative purposes.

Cash Flow Hedges

For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of March 31, 2025, we expect to reclassify $14 million of pre-tax net deferred gains associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions.

The cash flows associated with derivatives designated as cash flow hedges are recorded in All other operating activities – net in the Condensed Consolidated Statements of Cash Flows.

Net Investment Hedges

We use cross-currency interest rate swaps and foreign currency forward contracts in combination with foreign currency option contracts to hedge the foreign currency risk associated with our net investment in foreign operations. As of March 31, 2025, these contracts were designated as hedges of our net investment in foreign operations, primarily in Euro and Chinese Renminbi currencies.

The cash flows associated with derivatives designated as net investment hedges are recorded in All other investing activities – net in the Condensed Consolidated Statements of Cash Flows. Cash flows from the periodic interest settlements on the cross-currency swaps are recorded in All other operating activities – net in the Condensed Consolidated and Statements of Cash Flows.

Fair Value Hedges

We use interest rate swaps to hedge the interest rate risk on our fixed rate borrowings. These derivatives are designated as fair value hedges to hedge the changes in fair value due to benchmark interest rate risk of specific designated cash flows of our senior unsecured notes.

We record the changes in fair value on these swap contracts in Interest and other financial charges – net in our Condensed Consolidated Statements of Income, the same line item where the offsetting change in the fair value of the designated cash flows of the senior unsecured note is recorded as a basis adjustment.

Cash flows for the periodic interest settlements on the interest rate swaps are recorded in All other operating activities – net in the Condensed Consolidated Statements of Cash Flows.

Derivatives Not Designated as Hedging Instruments

We also execute derivative instruments, such as foreign currency forward contracts and equity-linked total return swaps, which are not designated as qualifying hedges. These derivatives serve as economic hedges of foreign currency exchange rate and equity price risks. We also identify and record foreign currency-related features in our purchase or sales contracts where the currency is not the local or functional currency of any substantive party to the contract as embedded derivatives.

The changes in fair value of derivatives not designated in qualifying hedge transactions are recorded in Cost of products, Cost of services, Selling, general, and administrative (“SG&A”), and Other (income) expense – net in the Condensed Consolidated Statements of Income based on the nature of the underlying hedged transaction. Changes in fair value of embedded derivatives are recognized in Other (income) expense – net in the Condensed Consolidated Statements of Income.

The cash flows associated with derivatives not designated but used as economic hedges are recorded, based on the nature of the underlying hedged transaction, in All other operating activities – net and All other investing activities – net in the Condensed Consolidated Statements of Cash Flows. The cash flows related to embedded derivatives are included in All other operating activities – net in the Condensed Consolidated Statements of Cash Flows.

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	March 31, 2025						December 31, 2024
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,474	$	25	$	15	$	1,210	$	43	$	11
Derivatives accounted for as cash flow hedges	1,474		25		15		1,210		43		11
Cross-currency swaps(1)	2,075		12		97		1,995		15		46
Foreign currency forward and options contracts	1,760		29		17		1,731		30		18
Derivatives accounted for as net investment hedges	3,835		41		114		3,726		45		64
Interest rate swaps(1)	2,700		17		14		2,700		—		51
Derivatives accounted for as fair value hedges	2,700		17		14		2,700		—		51
Foreign currency forward contracts	4,395		22		14		3,925		11		29
Other derivatives(1) (2)	384		31		2		370		47		—



Derivatives not designated as hedging instruments	4,779		53		16		4,294		57		29
Total derivatives	$	12,788	$	136	$	160	$	11,930	$	145	$	155

(1) As of March 31, 2025, accrued interest is included in the above fair value and is not considered material. As of December 31, 2024, accrued interest is excluded from the above fair value and is not considered material.

(2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges.


	March 31, 2025				December 31, 2024
	Carrying amount		Cumulative basis adjustment included in the carrying amount		Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated in fair value hedges	$	2,704	$	9	$	2,644	$	(51)

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis in our Condensed Consolidated Statements of Financial Position and in the table above.

As of March 31, 2025 and December 31, 2024, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $55 million and $77 million, respectively.

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the three months ended March 31
		2025		2024
Cash flow hedges		$	(14)	$	20
Net investment hedges(1)		(65)		32

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income.


Derivative Financial Instruments and Hedging Activity	For the three months ended March 31, 2025
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(2)	$	(1)	$	—	$	—	$	—
Effects of cash flow hedges	(2)		(1)		—		—		—
Cross-currency swaps	—		—		—		8		—
Foreign currency forward and options contracts	—		—		—		3		—
Effects of net investment hedges(1)	—		—		—		11		—

Interest rate swaps(2)	—		—		—		57		—
Debt basis adjustment on Long-term borrowings	—		—		—		(61)		—

Effects of fair value hedges	—		—		—		(4)		—
Foreign currency forward contracts	15		4		—		—		(1)



Other derivatives(3)	—		—		(3)		—		(15)
Effects of derivatives not designated as hedging instruments	15		4		(3)		—		(15)























	For the three months ended March 31, 2024
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(1)	$	—	$	—	$	—	$	—
Effects of cash flow hedges	(1)		—		—		—		—
Cross-currency swaps	—		—		—		8		—
Foreign currency forward and option contracts	—		—		—		2		—
Effects of net investment hedges(1)	—		—		—		10		—

Interest rate swaps(2)	—		—		—		(45)		—
Debt basis adjustment on Long-term borrowings	—		—		—		38		—

Effects of fair value hedges	—		—		—		(6)		—
Foreign currency forward contracts	(12)		(3)		—		—		—
Other derivatives(3)	—		—		5		—		20
Effects of derivatives not designated as hedging instruments	(12)		(3)		5		—		20

(1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the three months ended March 31, 2025 and 2024.

(2) Amount includes $(4) million and $(6) million of interest expense on interest rate derivatives for the three months ended March 31, 2025 and 2024, respectively.

(3) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

(4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income.

FAIR VALUE MEASUREMENTS.

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of March 31, 2025								As of December 31, 2024
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	—	$	230	$	—	$	230	$	—	$	312	$	—	$	312
Investment securities	27		—		—		27		32		—		—		32
Derivatives	—		136		—		136		—		145		—		145
Liabilities:
Derivatives	—		160		—		160		—		155		—		155
Contingent consideration	—		—		40		40		—		—		34		34

Cash equivalents

As of March 31, 2025 and December 31, 2024, Cash, cash equivalents, and restricted cash of $2,473 million and $2,889 million, respectively, included money market funds of $230 million and $312 million, and other cash equivalents of $1,229 million and $1,573 million, respectively. The carrying values of the other cash equivalents approximates the fair value due to their short maturities and are valued using Level 1 or Level 2 inputs. Refer to Note 16, “Supplemental Financial Information” for further information.

Derivatives

Derivatives are measured at fair value using a discounted cash flow method or option models using interest rates, foreign exchange spot and forward rates and yield curves observable at commonly quoted intervals, implied volatilities, and credit spreads as key inputs. Unobservable inputs relate to our own credit risk which is not significant to the overall measurement of fair value.

Contingent consideration

Contingent consideration is recorded at fair value based on estimates of future cash flows in connection with business acquisitions. As the valuation of these liabilities is based on inputs that are less observable or not observable in the market, the determination of fair value is classified within Level 3 of the fair value hierarchy.

Non-recurring fair value measurements

Changes in fair value measurements of assets and liabilities measured at fair value on a non-recurring basis, such as equity method investments, equity investments without readily determinable fair value, financing receivables, and long-lived assets, were not material for the three months ended March 31, 2025 and 2024, with the exception of the gain on fair value measurement of the NMP equity method investment as described in Note 7 “Acquisitions, Goodwill, and Other Intangible Assets.

Fair value of other financial instruments

The estimated fair value of borrowings as of March 31, 2025 and December 31, 2024 was $9,223 million and $9,374 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $8,759 million and $8,951 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” and Note 16, “Supplemental Financial Information” for further information.

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses, current	$ (3)	$ (2)
Current financing receivables – net	90	90
Allowance for credit losses, noncurrent	(4)	(4)
Non-current financing receivables – net	186	183
Loans receivable, at amortized cost
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	23	23
Non-current financing receivables, gross	35	35
Investment in finance leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	69	69
Non-current financing receivables, gross	$ 155	$ 152

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Cumulative Basis Adjustment for Fair value Hedges (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Long-term borrowings designated in fair value hedges	$ 2,704	$ 2,644
Hedged Liability, Statement of Financial Position [Extensible Enumeration]	Long-term borrowings	Long-term borrowings
Cumulative basis adjustment included in the carrying amount	$ 9	$ (51)

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Business Acquisitions

The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.


	Purchase consideration
Cash consideration, net of cash acquired	$	269
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	$	575

The estimated fair values of the assets and liabilities assumed in connection with the acquisition of NMP are as follows.


	Initial allocation
Receivables	$	53
Inventories	10
Property, plant, and equipment	243
Goodwill	216
Other intangible assets	223
All other non-current assets(1)	52
Deferred income taxes	(87)
All other non-current liabilities	(107)
Other(2)	(28)
Total net assets post acquisition	$	575

(1) All other non-current assets includes $12 million of indemnification assets, with the underlying indemnified liabilities recorded in All other non-current liabilities.

(2) Other includes Accounts payable, All other current liabilities, and Current compensation and benefits.

Schedule of Goodwill


	Imaging		AVS		PCS		PDx		Total



Balance at December 31, 2024	$	3,581	$	4,987	$	2,035	$	2,533	$	13,136

Acquisitions	—		—		—		216		216
Foreign currency exchange and other	5		12		2		1		20
Balance at March 31, 2025	$	3,587	$	4,999	$	2,037	$	2,750	$	13,373

Schedule of Finite-Lived Intangible Assets



	As of March 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	230	$	(26)	$	204	$	112	$	(24)	$	88
Patents and technology	2,668		(2,021)		647		2,593		(1,987)		606
Capitalized software	1,751		(1,479)		272		1,743		(1,437)		306
Trademarks and other	47		(29)		17		33		(29)		4
Total definite-lived assets	4,696		(3,555)		1,141		4,481		(3,477)		1,004
Indefinite-lived assets(1)	97		—		97		74		—		74
Total other intangible assets	$	4,793	$	(3,555)	$	1,238	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired in-process research and development prior to project completion and are not amortized.

Schedule of Indefinite-Lived Intangible Assets



	As of March 31, 2025						As of December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	230	$	(26)	$	204	$	112	$	(24)	$	88
Patents and technology	2,668		(2,021)		647		2,593		(1,987)		606
Capitalized software	1,751		(1,479)		272		1,743		(1,437)		306
Trademarks and other	47		(29)		17		33		(29)		4
Total definite-lived assets	4,696		(3,555)		1,141		4,481		(3,477)		1,004
Indefinite-lived assets(1)	97		—		97		74		—		74
Total other intangible assets	$	4,793	$	(3,555)	$	1,238	$	4,555	$	(3,477)	$	1,078

(1) Indefinite-lived intangible assets relate to acquired in-process research and development prior to project completion and are not amortized.

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

INCOME TAXES (Details)	3 Months Ended
INCOME TAXES (Details)	Mar. 31, 2025	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Effective income tax rate	15.00%	24.20%

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Contract assets	$ 572	$ 589
Other deferred assets	359	385
Contract and other deferred assets	931	974
Non-current contract assets	101	103
Non-current other deferred assets	113	105
Total contract and other deferred assets	$ 1,144	$ 1,183

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period	$ 188	$ 165
Net income attributable to redeemable noncontrolling interests	24	11
Balance at end of period	$ 211	$ 177

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Mar. 31, 2025	Mar. 31, 2024
Pay vs Performance Disclosure
Net income attributable to GE HealthCare	$ 564	$ 374

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

SEGMENT INFORMATION

Effective July 1, 2024, Image Guided Therapies, previously part of the Imaging segment, was realigned to the Ultrasound segment. The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (“AVS”). Following this realignment, the Company continues to have four reportable segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in Item 1, “Business” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure.

The Company’s organizational structure is based upon the availability of separate financial information that is evaluated regularly by the Company’s Chief Operating Decision Maker (“CODM”) for the purpose of assessing performance and allocating resources. The Company’s CODM is its Chief Executive Officer. The CODM assesses segment performance using Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gain (loss). Segment EBIT is also used in the annual budget and periodic forecasting processes and informs the CODM in decision making regarding the allocation of resources to the segments.


Total Revenues by Segment	For the three months ended March 31
		2025		2024
Total Imaging		$	2,140	$	2,062
AVS:
Procedural Guidance		641		651
Specialized Ultrasound		598		576
Total AVS		1,239		1,227
PCS:
Monitoring Solutions		556		527
Life Support Solutions		197		220
Total PCS		753		747
Total PDx		632		599
Other(1)		13		15
Total revenues		$	4,777	$	4,650

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HealthCare Financial Services (“HFS”) which does not meet the definition of an operating segment.


Significant Expenses by Segment	For the three months ended March 31
		2025		2024
Imaging:
Cost of sales		$	1,353	$	1,338
Other segment items(1)		588		559
Total Imaging		$	1,941	$	1,897
AVS:
Cost of sales		$	598	$	599
Other segment items(1)		380		371
Total AVS		$	978	$	970
PCS:
Cost of sales		$	481	$	460
Other segment items(1)		224		206
Total PCS		$	705	$	666
PDx:
Cost of sales		$	294	$	295
Other segment items(1)		133		126
Total PDx		$	428	$	421

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.


Segment EBIT	For the three months ended March 31
		2025		2024
Segment EBIT
Imaging		$	199	$	166
AVS		261		257
PCS		48		81
PDx		205		178
Other(1)		2		(1)
		715		681
Restructuring costs		(22)		(40)
Acquisition and disposition-related benefits (charges)		(8)		—
Gain (loss) on business and asset dispositions		10		—
Spin-Off and separation costs		(24)		(60)
Amortization of acquisition-related intangible assets		(35)		(31)
Investment revaluation gain (loss)		92		(20)
Interest and other financial charges – net		(110)		(122)
Non-operating benefit income (costs)		74		102
Income before income taxes		$	692	$	512

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS which does not meet the definition of an operating segment.

The following table represents the depreciation and amortization amounts reported within the Segment EBIT metric for our reportable segments. Depreciation and amortization expense related to shared property, plant, and equipment and intangibles, exclusive of acquisition-related intangible assets, has been fully allocated to our segments and those allocations are reflected in the amounts presented in the table below. These amounts are included within Cost of sales and Other segment items disclosed in the Significant Expenses by Segment table above.


Depreciation and Amortization by Segment	For the three months ended March 31
		2025		2024

Imaging		$	57	$	65
AVS		18		21
PCS		13		15
PDx		12		16

The Company does not report total assets by segment as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

POSTRETIREMENT BENEFIT PLANS - Components of Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Defined Benefit Plan Disclosure [Line Items]
Non-operating	$ (74)	$ (102)
Pension Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	1	8
Interest cost	249	242
Expected return on plan assets	(287)	(298)
Amortization of net loss (gain)	(20)	(17)
Amortization of prior service cost (credit)	(3)	2
Special termination cost	1	0
Non-operating	(60)	(71)
Net periodic expense (income)	(59)	(63)
Pension Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	5	5
Interest cost	36	35
Expected return on plan assets	(36)	(48)
Amortization of net loss (gain)	5	3
Amortization of prior service cost (credit)	(1)	0
Special termination cost	0	0
Non-operating	4	(10)
Net periodic expense (income)	9	(5)
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	1	2
Interest cost	13	13
Expected return on plan assets	0	0
Amortization of net loss (gain)	(15)	(15)
Amortization of prior service cost (credit)	(20)	(22)
Special termination cost	0	0
Non-operating	(21)	(24)
Net periodic expense (income)	$ (20)	$ (22)

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	$ 2,613		$ 2,629
Contract liabilities	724		$ 686
Contract liabilities, revenue recognized	$ 752	$ 741
Product \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, period	2 years
Service \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, period	5 years

BORROWINGS (Tables)

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

Schedule of Long-Term Borrowings


Borrowings Composition	As of
	March 31, 2025		December 31, 2024
5.600% senior notes due November 15, 2025	$	1,500	$	1,500
5.650% senior notes due November 15, 2027	1,750		1,750
4.800% senior notes due August 14, 2029	1,000		1,000
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility due January 2, 2026	500		750
Other	30		36
Total principal debt issued	8,780		9,036
Less: Unamortized debt issuance costs and discounts	30		33
Add: Cumulative basis adjustment for fair value hedges	9		(51)
Total borrowings	8,759		8,951
Less: Short-term borrowings(1)	2,002		1,502
Long-term borrowings	$	6,757	$	7,449

(1) Short-term borrowings as of March 31, 2025 and December 31, 2024 includes $2,000 million and $1,500 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

POSTRETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Defined Benefit Plan Disclosure [Line Items]
Plan asset or obligation reporting threshold	$ 50		$ 50
Defined benefit plan, expected future employer contributions, next fiscal year	327
Defined contribution plan, employer contribution amount	45	$ 32
Other Postretirement Benefits Plan
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, employer contribution amount	45
GE HealthCare Supplemental Pension Plan \| Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, employer contribution amount	43
Other Pension Plans \| Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, employer contribution amount	$ 10

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Sales allowances and related liabilities	$ 221	$ 242
Income and indirect tax liabilities including uncertain tax positions	286	279
Product warranties	171	168
Accrued freight and utilities	154	163
Operating lease liabilities	119	115
Derivative instruments	120	90
Interest payable on borrowings	141	92
Environmental and asset retirement obligations	17	17
Other	355	386
All other current liabilities	$ 1,583	$ 1,552

SUPPLEMENTAL FINANCIAL INFORMATION - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,661	$ 5,267
Accumulated depreciation	(3,179)	(3,080)
Right-of-use operating lease assets, net of amortization	369	364
Property, plant, and equipment – net	2,851	2,550
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	146	66
Buildings, structures, and related equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,107	1,943
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,905	2,705
Leasehold improvements and manufacturing plants under construction
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 503	$ 553

RECEIVABLES (Tables)

3 Months Ended

Mar. 31, 2025

Receivables [Abstract]

Schedule of Receivables


Current Receivables	As of
	March 31, 2025		December 31, 2024
Current customer receivables(1)	$	3,379	$	3,382
Non-income based tax receivables	155		155
Other sundry receivables	144		133
Current sundry receivables	299		287
Allowance for credit losses	(106)		(103)
Total current receivables – net	$	3,572	$	3,566

(1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $151 million and $153 million as of March 31, 2025 and December 31, 2024, respectively.


Long-Term Receivables	As of
	March 31, 2025		December 31, 2024
Long-term customer receivables	$	68	$	59
Non-income based tax receivables	23		20
Other sundry receivables	76		68
Long-term sundry receivables	99		88

Allowance for credit losses	(6)		(5)
Total long-term receivables – net	$	161	$	142



	As of
	March 31, 2025		December 31, 2024
Loans receivable, at amortized cost	$	23	$	23
Investment in finance leases, net of deferred income	69		69
Allowance for credit losses	(3)		(2)
Current financing receivables – net	$	90	$	90

Loans receivable, at amortized cost	$	35	$	35
Investment in finance leases, net of deferred income	155		152
Allowance for credit losses	(4)		(4)
Non-current financing receivables – net	$	186	$	183

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2025	Apr. 23, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2025
Document Transition Report	false
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		457,884,998
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net financing income and investment income (loss)	$ (1)	$ (16)
Equity method income (loss)	3	1
Change in fair value of assumed obligations	(8)	(8)
Gain on remeasurement of NMP equity method investment	97	0
Other items, net	8	14
Total other income (expense) – net	$ 99	$ (8)

- Definition

Amount of income (loss) for proportionate share of equity method investee's income (loss).

+ References + Details

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Tables)

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated other comprehensive income (loss) - net by component were as follows.


	For the three months ended March 31, 2025
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2024	$	(1,973)	$	576	$	18	$	(1,379)
Other comprehensive income (loss) before reclassifications – net of taxes of $15, $5, and $3	194		(20)		(11)		163
Reclassifications from AOCI – net of taxes(2)(3) of $—, $16, and $—	63		(49)		3		17
Other comprehensive income (loss)	257		(69)		(8)		180
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
March 31, 2025	$	(1,717)	$	507	$	10	$	(1,199)


	For the three months ended March 31, 2024
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2023	$	(1,706)	$	1,033	$	(18)	$	(691)
Other comprehensive income (loss) before reclassifications – net of taxes of $(7), $(1), and $(4)	(76)		2		15		(58)
Reclassifications from AOCI – net of taxes(2) of $—, $12, and $—	—		(38)		—		(37)
Other comprehensive income (loss)	(76)		(35)		16		(95)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
March 31, 2024	$	(1,781)	$	997	$	(2)	$	(787)

ORGANIZATION AND BASIS OF PRESENTATION	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION GE HealthCare Technologies Inc. is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. The condensed consolidated financial statements (the “financial statements”) of GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Operating results for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2024 period presented on the Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts. The financial statements and notes should be read in conjunction with the Company’s audited consolidated and combined financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. On January 3, 2023, the General Electric Company, which now operates as GE Aerospace (“GE”), completed the spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). Following this transaction, GE continues to be considered a related party due to the nature of our relationship and board member affiliation. Net costs incurred with GE were not significant for the three months ended March 31, 2025. Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation. On the Condensed Consolidated Statements of Cash Flows, new line items were added and amounts were reclassified accordingly for the following items: amounts related to current compensation and benefits that were previously reported within All other operating activities – net, amounts related to purchases of investments previously reported within All other investing activities – net, and amounts related to equity award activity previously reported within All other financing activities – net. Additionally, amounts due from related parties and due to related parties which were previously shown on separate lines on the Condensed Consolidated Statements of Cash Flows and Condensed Consolidated Statements of Financial Position were reclassified to Receivables, All other current assets, Accounts Payable, All other current liabilities, and All other operating activities - net as applicable. ESTIMATES AND ASSUMPTIONS. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. RECENT ACCOUNTING PRONOUNCEMENTS. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We expect the adoption to impact disclosures in our notes to the financial statements. In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 addresses investor requests for more transparency about expense information through the disaggregation of relevant expense captions in the notes to the financial statements. The provisions of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We expect the adoption to impact disclosures in our notes to the financial statements.

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Noncurrent Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid pension asset	$ 723	$ 657
Equity method and other investments	235	373
Financing receivables – net	186	183
Long-term receivables – net	161	142
Inventories	143	139
Contract and other deferred assets	213	208
Capitalized cloud computing arrangement implementation costs	113	84
Other	152	164
All other non-current assets	$ 1,926	$ 1,950

REVENUE RECOGNITION - Schedule of Remaining Performance Obligations (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations, amount	$ 14,879	$ 14,491
Products
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations, amount	4,599	4,755
Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations, amount	$ 10,280	$ 9,737

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses and deferred costs	$ 249	$ 188
Financing receivables – net	90	90
Derivative instruments	100	123
Tax receivables	116	115
Other	46	16
All other current assets	$ 601	$ 532

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 13,136
Acquisitions	216
Foreign currency exchange and other	20
Ending balance	13,373
Imaging
Goodwill [Roll Forward]
Beginning balance	3,581
Acquisitions	0
Foreign currency exchange and other	5
Ending balance	3,587
AVS
Goodwill [Roll Forward]
Beginning balance	4,987
Acquisitions	0
Foreign currency exchange and other	12
Ending balance	4,999
PCS
Goodwill [Roll Forward]
Beginning balance	2,035
Acquisitions	0
Foreign currency exchange and other	2
Ending balance	2,037
PDx
Goodwill [Roll Forward]
Beginning balance	2,533
Acquisitions	216
Foreign currency exchange and other	1
Ending balance	$ 2,750

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Principal debt issued	$ 8,780	$ 9,036
Less: Unamortized debt issuance costs and discounts	30	33
Add: Cumulative basis adjustment for fair value hedges	9	(51)
Total borrowings	8,759	8,951
Less: Short-term borrowings	2,002	1,502
Long-term borrowings	6,757	7,449
Long-term borrowings, current	$ 2,000	1,500
Senior notes \| 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 1,500	1,500
Senior notes \| 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750	1,750
Senior notes \| 4.800% senior notes due August 14, 2029
Debt Instrument [Line Items]
Stated interest rate	4.80%
Principal debt issued	$ 1,000	1,000
Senior notes \| 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250	1,250
Senior notes \| 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750	1,750
Senior notes \| 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000	1,000
Line of credit \| Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Principal debt issued	500	750
Other
Debt Instrument [Line Items]
Principal debt issued	$ 30	$ 36

REVENUE RECOGNITION (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Summary of Contract and Other Deferred Assets


	As of
	March 31, 2025		December 31, 2024
Contract assets	$	572	$	589
Other deferred assets	359		385
Contract and other deferred assets	931		974
Non-current contract assets(1)	101		103
Non-current other deferred assets(1)	113		105
Total contract and other deferred assets	$	1,144	$	1,183

(1)Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

Schedule of Remaining Performance Obligations


	As of
	March 31, 2025		December 31, 2024
Products	$	4,599	$	4,755
Services	10,280		9,737
Total RPO	$	14,879	$	14,491

RESTRUCTURING ACTIVITIES - Narrative (Details) $ in Millions	Mar. 31, 2025 USD ($)
Restructuring and Related Activities [Abstract]
Expected restructuring expense remaining	$ 40

POSTRETIREMENT BENEFIT PLANS (Tables)

3 Months Ended

Mar. 31, 2025

Retirement Benefits [Abstract]

Components of Net Periodic Expense


Components of Expense (Income)
	U.S. Plans				International Plans					OPEB Plans
For the three months ended March 31,	2025		2024			2025		2024			2025		2024
Service cost – Operating	$	1	$	8		$	5	$	5		$	1	$	2
Interest cost	249		242			36		35			13		13
Expected return on plan assets	(287)		(298)			(36)		(48)			—		—
Amortization of net loss (gain)	(20)		(17)			5		3			(15)		(15)
Amortization of prior service cost (credit)	(3)		2			(1)		—			(20)		(22)


Special termination cost	1		—			—		—			—		—
Non-operating	$	(60)	$	(71)		$	4	$	(10)		$	(21)	$	(24)
Net periodic expense (income)	$	(59)	$	(63)		$	9	$	(5)		$	(20)	$	(22)

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranties

An analysis of changes in the liability for product warranties follows.



	For the three months ended March 31
	2025		2024
Balance at beginning of period	$	168	$	192
Current-year provisions	59		41
Expenditures	(58)		(55)
Foreign currency exchange and other	2		(2)
Balance at end of period	$	171	$	175

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information


Total Revenues by Segment	For the three months ended March 31
		2025		2024
Total Imaging		$	2,140	$	2,062
AVS:
Procedural Guidance		641		651
Specialized Ultrasound		598		576
Total AVS		1,239		1,227
PCS:
Monitoring Solutions		556		527
Life Support Solutions		197		220
Total PCS		753		747
Total PDx		632		599
Other(1)		13		15
Total revenues		$	4,777	$	4,650


Significant Expenses by Segment	For the three months ended March 31
		2025		2024
Imaging:
Cost of sales		$	1,353	$	1,338
Other segment items(1)		588		559
Total Imaging		$	1,941	$	1,897
AVS:
Cost of sales		$	598	$	599
Other segment items(1)		380		371
Total AVS		$	978	$	970
PCS:
Cost of sales		$	481	$	460
Other segment items(1)		224		206
Total PCS		$	705	$	666
PDx:
Cost of sales		$	294	$	295
Other segment items(1)		133		126
Total PDx		$	428	$	421

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.


Segment EBIT	For the three months ended March 31
		2025		2024
Segment EBIT
Imaging		$	199	$	166
AVS		261		257
PCS		48		81
PDx		205		178
Other(1)		2		(1)
		715		681
Restructuring costs		(22)		(40)
Acquisition and disposition-related benefits (charges)		(8)		—
Gain (loss) on business and asset dispositions		10		—
Spin-Off and separation costs		(24)		(60)
Amortization of acquisition-related intangible assets		(35)		(31)
Investment revaluation gain (loss)		92		(20)
Interest and other financial charges – net		(110)		(122)
Non-operating benefit income (costs)		74		102
Income before income taxes		$	692	$	512

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS which does not meet the definition of an operating segment.


Depreciation and Amortization by Segment	For the three months ended March 31
		2025		2024

Imaging		$	57	$	65
AVS		18		21
PCS		13		15
PDx		12		16

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Supplier Finance Program [Line Items]
Supplier finance program obligation	$ 364	$ 394
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	180 days

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Numerator:
Net income	$ 588	$ 388
Net (income) loss attributable to noncontrolling interests	(24)	(14)
Net income attributable to GE HealthCare	$ 564	$ 374
Denominator:
Basic weighted-average shares outstanding	457	456
Dilutive effect of common stock equivalents (in shares)	2	3
Diluted weighted-average shares outstanding	459	459
Basic earnings per share (in dollars per share)	$ 1.23	$ 0.82
Diluted earnings per share (in dollars per share)	$ 1.23	$ 0.81
Antidilutive securities (in shares)	2	4

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 564	$ 374
Net income (loss) attributable to noncontrolling interests	24	14
Net income	588	388
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	257	(76)
Pension and Other Postretirement Plans – net of taxes	(69)	(35)
Cash flow hedges – net of taxes	(8)	16
Other comprehensive income (loss)	180	(95)
Comprehensive income (loss)	768	292
Less: Comprehensive income (loss) attributable to noncontrolling interests	24	14
Comprehensive income attributable to GE HealthCare	$ 744	$ 278

FINANCING RECEIVABLES - Narrative (Details)	Mar. 31, 2025	Dec. 31, 2024
Financing Receivable, Past Due [Line Items]
Financing receivable, nonaccrual, percent past due	3.00%	3.00%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	3.00%	4.00%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	3.00%	4.00%

RECEIVABLES

3 Months Ended

Mar. 31, 2025

Receivables [Abstract]

RECEIVABLES


Current Receivables	As of
	March 31, 2025		December 31, 2024
Current customer receivables(1)	$	3,379	$	3,382
Non-income based tax receivables	155		155
Other sundry receivables	144		133
Current sundry receivables	299		287
Allowance for credit losses	(106)		(103)
Total current receivables – net	$	3,572	$	3,566


Long-Term Receivables	As of
	March 31, 2025		December 31, 2024
Long-term customer receivables	$	68	$	59
Non-income based tax receivables	23		20
Other sundry receivables	76		68
Long-term sundry receivables	99		88

Allowance for credit losses	(6)		(5)
Total long-term receivables – net	$	161	$	142

Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

SEGMENT INFORMATION - Narrative (Details)	6 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Dec. 31, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	4
Number of operating segments	4

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 991	$ 921
Work in process	99	92
Finished goods	1,068	926
Inventories	$ 2,158	$ 1,939

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Receivables [Abstract]
Long-term customer receivables	$ 68	$ 59
Non-income based tax receivables	23	20
Other sundry receivables	76	68
Long-term sundry receivables	99	88
Allowance for credit losses	(6)	(5)
Total long-term receivables – net	$ 161	$ 142

RESTRUCTURING ACTIVITIES - Schedule of Restructuring Liability Activity (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Restructuring Reserve [Roll Forward]
Restructuring liabilities	$ 89		$ 86
Charges	$ 20
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of sales, Selling, general, and administrative	Cost of sales, Selling, general, and administrative
Payments and other adjustments	$ (17)
Employee termination costs
Restructuring Reserve [Roll Forward]
Restructuring liabilities	73		67
Charges	19
Payments and other adjustments	(14)
Facility and other exit costs
Restructuring Reserve [Roll Forward]
Restructuring liabilities	16		$ 18
Charges	1
Payments and other adjustments	$ (3)

RESTRUCTURING ACTIVITIES

3 Months Ended

Mar. 31, 2025

Restructuring and Related Activities [Abstract]

RESTRUCTURING ACTIVITIES

Restructuring activities are essential to optimize the business operating model for GE HealthCare and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring charges (gains) primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring activities are not allocated.

Net expenses for restructuring initiatives committed to by management through March 31, 2025 are included in the table below.


	For the three months ended March 31
		2025		2024
Employee termination costs		$	21	$	25
Facility and other exit costs		—		8
Asset write-downs		1		7
Total restructuring activities – net		$	22	$	40

These restructuring initiatives are expected to result in additional expenses of approximately $40 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Condensed Consolidated Statements of Income.

Liabilities related to restructuring are recognized within Current compensation and benefits, All other current liabilities, Non-current compensation and benefits, and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position. The activity related to our restructuring liabilities follows.


	Employee termination costs		Facility and other exit costs		Total




Balance at December 31, 2024	$	67	$	18	$	86
Charges	19		1		20
Payments and other adjustments	(14)		(3)		(17)
Balance at March 31, 2025	$	73	$	16	$	89

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 31, 2025	Mar. 31, 2025	Mar. 31, 2024
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		$ 8,464	$ 7,145
Other comprehensive income (loss) before reclassifications – net of taxes		163	(58)
Reclassifications from AOCI – net of taxes		17	(37)
Other comprehensive income (loss)		180	(95)
Less: Other comprehensive income (loss) attributable to noncontrolling interests		0	0
Equity, ending balance	$ 9,207	9,207	7,423
Nihon Medi-Physics
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Foreign currency translation gain, reclassification adjustment	63
Defined benefit pension plan loss, reclassification adjustment	8
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		(1,379)	(691)
Equity, ending balance	(1,199)	(1,199)	(787)
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		(1,973)	(1,706)
Other comprehensive income (loss) before reclassifications – net of taxes		194	(76)
Reclassifications from AOCI – net of taxes		63	0
Other comprehensive income (loss)		257	(76)
Less: Other comprehensive income (loss) attributable to noncontrolling interests		0	0
Equity, ending balance	(1,717)	(1,717)	(1,781)
Other comprehensive income (loss) before reclass, tax		15	(7)
Reclass from AOCI, tax		0	0
Pension and Other Postretirement Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		576	1,033
Other comprehensive income (loss) before reclassifications – net of taxes		(20)	2
Reclassifications from AOCI – net of taxes		(49)	(38)
Other comprehensive income (loss)		(69)	(35)
Less: Other comprehensive income (loss) attributable to noncontrolling interests		0	0
Equity, ending balance	507	507	997
Other comprehensive income (loss) before reclass, tax		5	(1)
Reclass from AOCI, tax		16	12
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		18	(18)
Other comprehensive income (loss) before reclassifications – net of taxes		(11)	15
Reclassifications from AOCI – net of taxes		3	0
Other comprehensive income (loss)		(8)	16
Less: Other comprehensive income (loss) attributable to noncontrolling interests		0	0
Equity, ending balance	$ 10	10	(2)
Other comprehensive income (loss) before reclass, tax		3	(4)
Reclass from AOCI, tax		$ 0	$ 0

Condensed Consolidated Statements of Financial Position (Unaudited) (Parentheticals) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 106	$ 103
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	458,134,263	457,246,971
Treasury stock (in shares)	291,053	291,053

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

Schedule of Earnings per Share


Earnings Per Share	For the three months ended March 31
(In millions, except per share amounts)		2025		2024
Numerator:
Net income		$	588	$	388
Net (income) loss attributable to noncontrolling interests		(24)		(14)
Net income attributable to GE HealthCare		564		374


Denominator:
Basic weighted-average shares outstanding		457		456
Dilutive effect of common stock equivalents		2		3
Diluted weighted-average shares outstanding		459		459

Basic earnings per share		$	1.23	$	0.82



Diluted earnings per share		1.23		0.81


Antidilutive securities(1)		2		4

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORMATION

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.


	As of
	March 31, 2025		December 31, 2024
Cash and cash equivalents	$	2,454	$	2,874
Short-term restricted cash	19		16
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position	2,473		2,889
Long-term restricted cash(1)	3		3
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows	$	2,476	$	2,893

(1) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

INVENTORIES.


	As of
	March 31, 2025		December 31, 2024
Raw materials	$	991	$	921
Work in process	99		92
Finished goods	1,068		926
Inventories	$	2,158	$	1,939

Certain inventory items are long-term in nature and therefore have been recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position and are not reflected in the table above. See the supplemental table “All Other Non-Current Assets” for further information.

PROPERTY, PLANT, AND EQUIPMENT – NET.


	As of
	March 31, 2025		December 31, 2024
Land and improvements	$	146	$	66
Buildings, structures, and related equipment	2,107		1,943
Machinery and equipment	2,905		2,705
Leasehold improvements and manufacturing plants under construction	503		553
Total property, plant, and equipment, at original cost	5,661		5,267
Accumulated depreciation	(3,179)		(3,080)
Right-of-use operating lease assets, net of amortization	369		364
Property, plant, and equipment – net	$	2,851	$	2,550

ALL OTHER ASSETS AND ALL OTHER LIABILITIES.


All Other Current Assets	As of
	March 31, 2025		December 31, 2024
Prepaid expenses and deferred costs	$	249	$	188
Financing receivables – net	90		90
Derivative instruments(1)	100		123
Tax receivables	116		115
Other(2)	46		16
All other current assets	$	601	$	532


All Other Non-Current Assets	As of
	March 31, 2025		December 31, 2024
Prepaid pension asset	$	723	$	657
Equity method and other investments	235		373
Financing receivables – net	186		183
Long-term receivables – net	161		142
Inventories	143		139
Contract and other deferred assets	213		208
Capitalized cloud computing arrangement implementation costs	113		84
Other(3)	152		164
All other non-current assets	$	1,926	$	1,950


All Other Current Liabilities	As of
	March 31, 2025		December 31, 2024
Sales allowances and related liabilities	$	221	$	242
Income and indirect tax liabilities including uncertain tax positions	286		279
Product warranties	171		168
Accrued freight and utilities	154		163
Operating lease liabilities	119		115
Derivative instruments(1)	120		90
Interest payable on borrowings	141		92
Environmental and asset retirement obligations	17		17
Other(4)	355		386
All other current liabilities	$	1,583	$	1,552


All Other Non-Current Liabilities	As of
	March 31, 2025		December 31, 2024
Contract liabilities	$	724	$	686
Operating lease liabilities	266		270
Environmental and asset retirement obligations	395		291
Income and indirect tax liabilities including uncertain tax positions	170		237
Derivative instruments(1)	39		64
Finance lease obligations	40		40
Sales allowances and related liabilities	24		23
Other(5)	182		184
All other non-current liabilities	$	1,840	$	1,796

(1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information.

(2) Current assets Other primarily represents indemnity assets associated with separation agreements with GE as of March 31, 2025.

(3) Non-current assets Other primarily consists of indemnity assets associated with separation agreements with GE, derivative instruments, and tax receivables.

(4) Current liabilities Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and dividends payable to stockholders.

(5) Non-current liabilities Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.

SUPPLY CHAIN FINANCE PROGRAMS.

The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables to borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 180 days, depending on the underlying supplier agreements.

Included within Accounts payable in the Condensed Consolidated Statements of Financial Position as of March 31, 2025 and December 31, 2024 were $364 million and $394 million, respectively, of confirmed supplier invoices that are outstanding and subject to third-party programs.

REDEEMABLE NONCONTROLLING INTERESTS.

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable, or probable of becoming redeemable, are subsequently adjusted to the greater of current redemption value or initial carrying value.

Activity attributable to redeemable noncontrolling interests is presented below.


	For the three months ended March 31
	2025		2024
Balance at beginning of period	$	188	$	165
Net income attributable to redeemable noncontrolling interests	24		11


Balance at end of period	$	211	$	177

OTHER INCOME (EXPENSE) – NET.


	For the three months ended March 31
		2025		2024
Net financing income and investment income (loss)		$	(1)	$	(16)
Equity method income (loss)		3		1
Change in fair value of assumed obligations		(8)		(8)
Gain on remeasurement of NMP equity method investment(1)		97		—
Other items, net(2)		8		14
Total other income (expense) – net		$	99	$	(8)

(1) Refer to Note 7, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	$ 4,696	$ 4,481
Accumulated Amortization	(3,555)	(3,477)
Finite-lived assets, net	1,141	1,004
Indefinite-lived assets	97	74
Gross Carrying Amount	4,793	4,555
Net	1,238	1,078
Customer-related
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	230	112
Accumulated Amortization	(26)	(24)
Finite-lived assets, net	204	88
Patents and technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	2,668	2,593
Accumulated Amortization	(2,021)	(1,987)
Finite-lived assets, net	647	606
Capitalized software
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	1,751	1,743
Accumulated Amortization	(1,479)	(1,437)
Finite-lived assets, net	272	306
Trademarks and other
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	47	33
Accumulated Amortization	(29)	(29)
Finite-lived assets, net	$ 17	$ 4

LEASES (Details) - USD ($) $ in Millions	3 Months Ended
LEASES (Details) - USD ($) $ in Millions	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Leases [Abstract]
Operating lease liabilities	$ 386		$ 385
Lease expense	$ 62	$ 60

REVENUE RECOGNITION

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services.

CONTRACT AND OTHER DEFERRED ASSETS.

Contract assets reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.


	As of
	March 31, 2025		December 31, 2024
Contract assets	$	572	$	589
Other deferred assets	359		385
Contract and other deferred assets	931		974
Non-current contract assets(1)	101		103
Non-current other deferred assets(1)	113		105
Total contract and other deferred assets	$	1,144	$	1,183

(1)Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

CONTRACT LIABILITIES.

Contract liabilities include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which these remaining performance obligations are expected to be satisfied with our customers.

As of March 31, 2025 and December 31, 2024, contract liabilities were approximately $2,613 million and $2,629 million, respectively, of which the non-current portion of $724 million and $686 million, respectively, was recognized in All other non-current liabilities in the Condensed Consolidated Statements of Financial Position. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $752 million and $741 million for the three months ended March 31, 2025 and 2024, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining performance obligations (“RPO”) represents the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the right to cancel or terminate without incurring a substantive penalty. RPO also excludes estimated revenue from arrangements where we lease equipment manufactured by the Company to customers.


	As of
	March 31, 2025		December 31, 2024
Products	$	4,599	$	4,755
Services	10,280		9,737
Total RPO	$	14,879	$	14,491

We expect to recognize substantially all of the revenue for our product-related RPO within two years and services-related RPO within five years.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Derivative [Line Items]
Gross Notional	$ 12,788	$ 11,930
Fair Value – Assets	136	145
Fair Value – Liabilities	160	155
Designated as hedging instrument \| Cash flow hedges
Derivative [Line Items]
Gross Notional	1,474	1,210
Fair Value – Assets	25	43
Fair Value – Liabilities	15	11
Designated as hedging instrument \| Cash flow hedges \| Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	1,474	1,210
Fair Value – Assets	25	43
Fair Value – Liabilities	15	11
Designated as hedging instrument \| Net investment hedges
Derivative [Line Items]
Gross Notional	3,835	3,726
Fair Value – Assets	41	45
Fair Value – Liabilities	114	64
Designated as hedging instrument \| Net investment hedges \| Cross-currency swaps
Derivative [Line Items]
Gross Notional	2,075	1,995
Fair Value – Assets	12	15
Fair Value – Liabilities	97	46
Designated as hedging instrument \| Net investment hedges \| Foreign currency forward and options contracts
Derivative [Line Items]
Gross Notional	1,760	1,731
Fair Value – Assets	29	30
Fair Value – Liabilities	17	18
Designated as hedging instrument \| Fair value hedges
Derivative [Line Items]
Gross Notional	2,700	2,700
Fair Value – Assets	17	0
Fair Value – Liabilities	14	51
Designated as hedging instrument \| Fair value hedges \| Interest rate swaps
Derivative [Line Items]
Gross Notional	2,700	2,700
Fair Value – Assets	17	0
Fair Value – Liabilities	14	51
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	4,779	4,294
Fair Value – Assets	53	57
Fair Value – Liabilities	16	29
Not designated as hedging instrument \| Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	4,395	3,925
Fair Value – Assets	22	11
Fair Value – Liabilities	14	29
Not designated as hedging instrument \| Other derivatives
Derivative [Line Items]
Gross Notional	384	370
Fair Value – Assets	31	47
Fair Value – Liabilities	$ 2	$ 0

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Mar. 31, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTSOn April 30, 2025, our Board of Directors authorized a share repurchase program for up to $1,000 million of our common stock. Repurchases may be made from time to time in the open market, in privately negotiated transactions, or in such other manner as determined by GE HealthCare. The repurchase program does not have an expiration date, does not obligate GE HealthCare to acquire any particular amount of common stock, and may be suspended or terminated at any time at the Company's discretion.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Cash flow hedges	$ (14)	$ 20
Net investment hedges	$ (65)	$ 32

FINANCING RECEIVABLES

3 Months Ended

Mar. 31, 2025

Receivables [Abstract]

FINANCING RECEIVABLES

Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position.



	As of
	March 31, 2025		December 31, 2024
Loans receivable, at amortized cost	$	23	$	23
Investment in finance leases, net of deferred income	69		69
Allowance for credit losses	(3)		(2)
Current financing receivables – net	$	90	$	90

Loans receivable, at amortized cost	$	35	$	35
Investment in finance leases, net of deferred income	155		152
Allowance for credit losses	(4)		(4)
Non-current financing receivables – net	$	186	$	183

As of March 31, 2025, 3%, 3%, and 3% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2024, 4%, 4%, and 3% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 2,454	$ 2,874
Short-term restricted cash	19	16
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position	2,473	2,889
Long-term restricted cash	3	3
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows	$ 2,476	$ 2,893	$ 2,565	$ 2,506

RESTRUCTURING ACTIVITIES (Tables)

3 Months Ended

Mar. 31, 2025

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Activities

Net expenses for restructuring initiatives committed to by management through March 31, 2025 are included in the table below.


	For the three months ended March 31
		2025		2024
Employee termination costs		$	21	$	25
Facility and other exit costs		—		8
Asset write-downs		1		7
Total restructuring activities – net		$	22	$	40

The activity related to our restructuring liabilities follows.


	Employee termination costs		Facility and other exit costs		Total




Balance at December 31, 2024	$	67	$	18	$	86
Charges	19		1		20
Payments and other adjustments	(14)		(3)		(17)
Balance at March 31, 2025	$	73	$	16	$	89

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Receivables [Abstract]
Current customer receivables	$ 3,379	$ 3,382
Non-income based tax receivables	155	155
Other sundry receivables	144	133
Current sundry receivables	299	287
Allowance for credit losses	(106)	(103)
Total current receivables – net	3,572	3,566
Chargebacks	$ 151	$ 153

SUBSEQUENT EVENTS (Details) $ in Millions	Apr. 30, 2025 USD ($)
Subsequent event
Subsequent Event [Line Items]
Share repurchase program, authorized amount	$ 1,000

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2023		455,000,000
Equity, beginning balance at Dec. 31, 2023	$ 7,145	$ 5		$ 6,493	$ 1,326	$ (691)	$ 12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity awards, net of shares withheld for taxes and other (in shares)		1,000,000
Issuance of shares under equity awards, net of shares withheld for taxes and other	(24)			(24)
Net income attributable to GE HealthCare	374				374
Dividends declared	(14)				(14)
Other comprehensive income (loss) attributable to GE HealthCare	(95)					(95)
Changes in equity attributable to noncontrolling interests	2						2
Share-based compensation	34			34
Equity, ending balance (in shares) at Mar. 31, 2024		456,000,000
Equity, ending balance at Mar. 31, 2024	$ 7,423	$ 5		6,504	1,687	(787)	14
Equity, beginning balance (in shares) at Dec. 31, 2024	457,246,971	457,000,000
Equity, beginning balance at Dec. 31, 2024	$ 8,464	$ 5	$ (25)	6,583	3,262	(1,379)	18
Treasury stock, beginning balance (in shares) at Dec. 31, 2024	291,053		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity awards, net of shares withheld for taxes and other (in shares)		1,000,000
Issuance of shares under equity awards, net of shares withheld for taxes and other	$ (9)			(9)
Net income attributable to GE HealthCare	564				564
Dividends declared	(16)				(16)
Other comprehensive income (loss) attributable to GE HealthCare	180					180
Changes in equity attributable to noncontrolling interests	1						1
Share-based compensation	$ 22			22
Equity, ending balance (in shares) at Mar. 31, 2025	458,134,263	458,000,000
Equity, ending balance at Mar. 31, 2025	$ 9,207	$ 5	$ (25)	$ 6,597	$ 3,810	$ (1,199)	$ 20
Treasury stock, ending balance (in shares) at Mar. 31, 2025	291,053		0

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 31, 2025
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Our effective income tax rate was 15.0% and 24.2% for the three months ended March 31, 2025 and 2024, respectively. The tax rate for the three months ended March 31, 2025 is lower than the U.S. statutory rate primarily due to the release of income tax reserves in a foreign jurisdiction for tax years which are no longer subject to an assessment from the local taxing authorities, the remeasurement gain that was recorded due to the NMP acquisition which is not taxable, and research and development (“R&D”) benefits, partially offset by geographic earnings mix, withholding taxes, and state taxes. The tax rate for the three months ended March 31, 2024 is higher than the U.S. statutory rate primarily due to geographic earnings mix, withholding taxes, and state taxes, partially offset by R&D benefits. The Company is currently being audited in a number of jurisdictions for tax years 2004-2023, including China, France, Germany, India, Japan, Norway, the United Kingdom, and the United States.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Total revenues	$ 4,777	$ 4,650
Gross profit	2,012	1,902
Selling, general, and administrative	1,040	1,038
Research and development	344	324
Total operating expenses	1,383	1,362
Operating income	629	540
Interest and other financial charges – net	110	122
Non-operating benefit (income) costs	(74)	(102)
Other (income) expense – net	(99)	8
Income before income taxes	692	512
Benefit (provision) for income taxes	(104)	(124)
Net income	588	388
Net (income) loss attributable to noncontrolling interests	(24)	(14)
Net income attributable to GE HealthCare	$ 564	$ 374
Earnings per share attributable to GE HealthCare:
Basic (in dollars per share)	$ 1.23	$ 0.82
Diluted (in dollars per share)	$ 1.23	$ 0.81
Weighted-average number of shares outstanding:
Basic (in shares)	457	456
Diluted (in shares)	459	459
Product
Total revenues	$ 3,117	$ 3,045
Cost of sales	1,963	1,967
Service
Total revenues	1,660	1,605
Cost of sales	$ 802	$ 782

FINANCING RECEIVABLES (Tables)

3 Months Ended

Mar. 31, 2025

Receivables [Abstract]

Schedule of Receivables


Current Receivables	As of
	March 31, 2025		December 31, 2024
Current customer receivables(1)	$	3,379	$	3,382
Non-income based tax receivables	155		155
Other sundry receivables	144		133
Current sundry receivables	299		287
Allowance for credit losses	(106)		(103)
Total current receivables – net	$	3,572	$	3,566


Long-Term Receivables	As of
	March 31, 2025		December 31, 2024
Long-term customer receivables	$	68	$	59
Non-income based tax receivables	23		20
Other sundry receivables	76		68
Long-term sundry receivables	99		88

Allowance for credit losses	(6)		(5)
Total long-term receivables – net	$	161	$	142



	As of
	March 31, 2025		December 31, 2024
Loans receivable, at amortized cost	$	23	$	23
Investment in finance leases, net of deferred income	69		69
Allowance for credit losses	(3)		(2)
Current financing receivables – net	$	90	$	90

Loans receivable, at amortized cost	$	35	$	35
Investment in finance leases, net of deferred income	155		152
Allowance for credit losses	(4)		(4)
Non-current financing receivables – net	$	186	$	183

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 168	$ 192
Current-year provisions	59	41
Expenditures	(58)	(55)
Foreign currency exchange and other	2	(2)
Balance at end of period	$ 171	$ 175

SEGMENT INFORMATION - Schedule of Significant Expenses by Segment (Details) - Operating segments - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Imaging
Segment Reporting Information [Line Items]
Cost of sales	$ 1,353	$ 1,338
Other segment items	588	559
Total expenses	1,941	1,897
AVS
Segment Reporting Information [Line Items]
Cost of sales	598	599
Other segment items	380	371
Total expenses	978	970
PCS
Segment Reporting Information [Line Items]
Cost of sales	481	460
Other segment items	224	206
Total expenses	705	666
PDx
Segment Reporting Information [Line Items]
Cost of sales	294	295
Other segment items	133	126
Total expenses	$ 428	$ 421

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

+ Details

Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share)	$ 0.035	$ 0.03

SEGMENT INFORMATION - Schedule of Depreciation and Amortization by Segment (Details) - Operating segments - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Imaging
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 57	$ 65
AVS
Segment Reporting Information [Line Items]
Depreciation and amortization	18	21
PCS
Segment Reporting Information [Line Items]
Depreciation and amortization	13	15
PDx
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 12	$ 16

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

Schedule of Derivative Assets at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	March 31, 2025						December 31, 2024
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,474	$	25	$	15	$	1,210	$	43	$	11
Derivatives accounted for as cash flow hedges	1,474		25		15		1,210		43		11
Cross-currency swaps(1)	2,075		12		97		1,995		15		46
Foreign currency forward and options contracts	1,760		29		17		1,731		30		18
Derivatives accounted for as net investment hedges	3,835		41		114		3,726		45		64
Interest rate swaps(1)	2,700		17		14		2,700		—		51
Derivatives accounted for as fair value hedges	2,700		17		14		2,700		—		51
Foreign currency forward contracts	4,395		22		14		3,925		11		29
Other derivatives(1) (2)	384		31		2		370		47		—



Derivatives not designated as hedging instruments	4,779		53		16		4,294		57		29
Total derivatives	$	12,788	$	136	$	160	$	11,930	$	145	$	155

(2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

Schedule of Derivative Liabilities at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	March 31, 2025						December 31, 2024
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,474	$	25	$	15	$	1,210	$	43	$	11
Derivatives accounted for as cash flow hedges	1,474		25		15		1,210		43		11
Cross-currency swaps(1)	2,075		12		97		1,995		15		46
Foreign currency forward and options contracts	1,760		29		17		1,731		30		18
Derivatives accounted for as net investment hedges	3,835		41		114		3,726		45		64
Interest rate swaps(1)	2,700		17		14		2,700		—		51
Derivatives accounted for as fair value hedges	2,700		17		14		2,700		—		51
Foreign currency forward contracts	4,395		22		14		3,925		11		29
Other derivatives(1) (2)	384		31		2		370		47		—



Derivatives not designated as hedging instruments	4,779		53		16		4,294		57		29
Total derivatives	$	12,788	$	136	$	160	$	11,930	$	145	$	155

(2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

Schedule of Effect of Derivatives Instruments on Statement of Financial Position and Statement of Income

The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges.


	March 31, 2025				December 31, 2024
	Carrying amount		Cumulative basis adjustment included in the carrying amount		Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated in fair value hedges	$	2,704	$	9	$	2,644	$	(51)

The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income.


Derivative Financial Instruments and Hedging Activity	For the three months ended March 31, 2025
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(2)	$	(1)	$	—	$	—	$	—
Effects of cash flow hedges	(2)		(1)		—		—		—
Cross-currency swaps	—		—		—		8		—
Foreign currency forward and options contracts	—		—		—		3		—
Effects of net investment hedges(1)	—		—		—		11		—

Interest rate swaps(2)	—		—		—		57		—
Debt basis adjustment on Long-term borrowings	—		—		—		(61)		—

Effects of fair value hedges	—		—		—		(4)		—
Foreign currency forward contracts	15		4		—		—		(1)



Other derivatives(3)	—		—		(3)		—		(15)
Effects of derivatives not designated as hedging instruments	15		4		(3)		—		(15)























	For the three months ended March 31, 2024
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(1)	$	—	$	—	$	—	$	—
Effects of cash flow hedges	(1)		—		—		—		—
Cross-currency swaps	—		—		—		8		—
Foreign currency forward and option contracts	—		—		—		2		—
Effects of net investment hedges(1)	—		—		—		10		—

Interest rate swaps(2)	—		—		—		(45)		—
Debt basis adjustment on Long-term borrowings	—		—		—		38		—

Effects of fair value hedges	—		—		—		(6)		—
Foreign currency forward contracts	(12)		(3)		—		—		—
Other derivatives(3)	—		—		5		—		20
Effects of derivatives not designated as hedging instruments	(12)		(3)		5		—		20

(1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the three months ended March 31, 2025 and 2024.

(2) Amount includes $(4) million and $(6) million of interest expense on interest rate derivatives for the three months ended March 31, 2025 and 2024, respectively.

(3) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

(4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income.

Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the three months ended March 31
		2025		2024
Cash flow hedges		$	(14)	$	20
Net investment hedges(1)		(65)		32

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of March 31, 2025								As of December 31, 2024
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	—	$	230	$	—	$	230	$	—	$	312	$	—	$	312
Investment securities	27		—		—		27		32		—		—		32
Derivatives	—		136		—		136		—		145		—		145
Liabilities:
Derivatives	—		160		—		160		—		155		—		155
Contingent consideration	—		—		40		40		—		—		34		34

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION (Policies)	Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	The condensed consolidated financial statements (the “financial statements”) of GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Operating results for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2024 period presented on the Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.
RECLASSIFICATION	Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation. On the Condensed Consolidated Statements of Cash Flows, new line items were added and amounts were reclassified accordingly for the following items: amounts related to current compensation and benefits that were previously reported within All other operating activities – net, amounts related to purchases of investments previously reported within All other investing activities – net, and amounts related to equity award activity previously reported within All other financing activities – net. Additionally, amounts due from related parties and due to related parties which were previously shown on separate lines on the Condensed Consolidated Statements of Cash Flows and Condensed Consolidated Statements of Financial Position were reclassified to Receivables, All other current assets, Accounts Payable, All other current liabilities, and All other operating activities - net as applicable.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We expect the adoption to impact disclosures in our notes to the financial statements. In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 addresses investor requests for more transparency about expense information through the disaggregation of relevant expense captions in the notes to the financial statements. The provisions of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We expect the adoption to impact disclosures in our notes to the financial statements.
SUPPLY CHAIN FINANCE PROGRAMS	The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables to borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 180 days, depending on the underlying supplier agreements.

POSTRETIREMENT BENEFIT PLANS

3 Months Ended

Mar. 31, 2025

Retirement Benefits [Abstract]

POSTRETIREMENT BENEFIT PLANS

We sponsor a number of pension and retiree health and life insurance benefit plans that we present in three categories: U.S. Plans, International Plans, and Other Postretirement Plans (“OPEB Plans”). Please refer to Note 10, “Postretirement Benefit Plans” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for further information. Pension plans with pension assets or obligations less than $50 million are not included in the results below.


Components of Expense (Income)
	U.S. Plans				International Plans					OPEB Plans
For the three months ended March 31,	2025		2024			2025		2024			2025		2024
Service cost – Operating	$	1	$	8		$	5	$	5		$	1	$	2
Interest cost	249		242			36		35			13		13
Expected return on plan assets	(287)		(298)			(36)		(48)			—		—
Amortization of net loss (gain)	(20)		(17)			5		3			(15)		(15)
Amortization of prior service cost (credit)	(3)		2			(1)		—			(20)		(22)


Special termination cost	1		—			—		—			—		—
Non-operating	$	(60)	$	(71)		$	4	$	(10)		$	(21)	$	(24)
Net periodic expense (income)	$	(59)	$	(63)		$	9	$	(5)		$	(20)	$	(22)

In the three months ended March 31, 2025, the Company made cash payments totaling $43 million to its U.S. Plans, $10 million to its International Plans, and $45 million to its OPEB Plans. In 2025, the Company expects to make total cash contributions of approximately $327 million to these plans. The Company funds annually, at a minimum, the statutorily required minimum amount for our qualified plans. Non-qualified plans are unfunded and we pay benefits from our cash on hand.

Defined Contribution Plan

GE HealthCare sponsors a defined contribution plan for its eligible U.S. employees. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan were $45 million and $32 million for the three months ended March 31, 2025 and 2024, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

+ Details

BORROWINGS

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

BORROWINGS

The Company’s borrowings include the following senior unsecured notes and credit agreements:

Senior Unsecured Notes

The Company’s borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”).

Credit Facilities

In the first quarter of 2025, the Company terminated its existing five-year and 364-day senior unsecured revolving credit facilities. These were replaced with new five-year and 364-day senior unsecured revolving credit facilities in aggregate committed amounts of $3,000 million and $500 million, respectively. The terms of the new facilities are substantially similar to those of the terminated facilities.

The Company has credit agreements providing for:

•a five-year senior unsecured revolving credit facility in an aggregate committed amount of $3,000 million, maturing on March 27, 2030;

•a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $500 million, maturing on March 26, 2026; and

•a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million, maturing on January 2, 2026 (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”).

There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $500 million and $750 million outstanding on the Term Loan Facility as of March 31, 2025 and December 31, 2024, respectively. In the first quarter of 2025, we repaid $250 million of the Term Loan Facility.


Borrowings Composition	As of
	March 31, 2025		December 31, 2024
5.600% senior notes due November 15, 2025	$	1,500	$	1,500
5.650% senior notes due November 15, 2027	1,750		1,750
4.800% senior notes due August 14, 2029	1,000		1,000
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility due January 2, 2026	500		750
Other	30		36
Total principal debt issued	8,780		9,036
Less: Unamortized debt issuance costs and discounts	30		33
Add: Cumulative basis adjustment for fair value hedges	9		(51)
Total borrowings	8,759		8,951
Less: Short-term borrowings(1)	2,002		1,502
Long-term borrowings	$	6,757	$	7,449

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

As of March 31, 2025 and December 31, 2024, the Company had bank guarantees and surety bonds of approximately $786 million and $784 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $24 million and $25 million of guarantees as of March 31, 2025 and December 31, 2024, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated Statements of Financial Position reflect a liability of $2 million and $3 million as of March 31, 2025 and December 31, 2024, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Condensed Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Cash, cash equivalents, and restricted cash	$ 2,473	$ 2,889
Receivables – net of allowances of $106 and $103	3,572	3,566
Inventories	2,158	1,939
Contract and other deferred assets	931	974
All other current assets	601	532
Current assets	9,735	9,901
Property, plant, and equipment – net	2,851	2,550
Goodwill	13,373	13,136
Other intangible assets – net	1,238	1,078
Deferred income taxes	4,462	4,474
All other non-current assets	1,926	1,950
Total assets	33,586	33,089
Short-term borrowings	2,002	1,502
Accounts payable	3,152	3,035
Contract liabilities	1,889	1,943
Current compensation and benefits	1,343	1,521
All other current liabilities	1,583	1,552
Current liabilities	9,969	9,553
Long-term borrowings	6,757	7,449
Non-current compensation and benefits	5,443	5,583
Deferred income taxes	159	56
All other non-current liabilities	1,840	1,796
Total liabilities	24,168	24,437
Commitments and contingencies
Redeemable noncontrolling interests	211	188
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 458,134,263 shares issued as of March 31, 2025; 457,246,971 shares issued as of December 31, 2024	5	5
Treasury stock, at cost, 291,053 shares as of March 31, 2025 and December 31, 2024	(25)	(25)
Additional paid-in capital	6,597	6,583
Retained earnings	3,810	3,262
Accumulated other comprehensive income (loss) – net	(1,199)	(1,379)
Total equity attributable to GE HealthCare	9,187	8,446
Noncontrolling interests	20	18
Total equity	9,207	8,464
Total liabilities, redeemable noncontrolling interests, and equity	$ 33,586	$ 33,089

SEGMENT INFORMATION - Schedule of Revenues by Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Total revenues	$ 4,777	$ 4,650
Operating segments \| Imaging
Segment Reporting Information [Line Items]
Total revenues	2,140	2,062
Operating segments \| AVS
Segment Reporting Information [Line Items]
Total revenues	1,239	1,227
Operating segments \| AVS \| Procedural Guidance
Segment Reporting Information [Line Items]
Total revenues	641	651
Operating segments \| AVS \| Specialized Ultrasound
Segment Reporting Information [Line Items]
Total revenues	598	576
Operating segments \| PCS
Segment Reporting Information [Line Items]
Total revenues	753	747
Operating segments \| PCS \| Monitoring Solutions
Segment Reporting Information [Line Items]
Total revenues	556	527
Operating segments \| PCS \| Life Support Solutions
Segment Reporting Information [Line Items]
Total revenues	197	220
Operating segments \| PDx
Segment Reporting Information [Line Items]
Total revenues	632	599
Other
Segment Reporting Information [Line Items]
Total revenues	$ 13	$ 15

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Assets:
Money market funds	$ 2,473	$ 2,889
Recurring
Assets:
Investment securities	27	32
Derivatives	136	145
Liabilities:
Derivatives	160	155
Contingent consideration	40	34
Recurring \| Money market funds
Assets:
Money market funds	230	312
Level 1 \| Recurring
Assets:
Investment securities	27	32
Derivatives	0	0
Liabilities:
Derivatives	0	0
Contingent consideration	0	0
Level 1 \| Recurring \| Money market funds
Assets:
Money market funds	0	0
Level 2 \| Recurring
Assets:
Investment securities	0	0
Derivatives	136	145
Liabilities:
Derivatives	160	155
Contingent consideration	0	0
Level 2 \| Recurring \| Money market funds
Assets:
Money market funds	230	312
Level 3 \| Recurring
Assets:
Investment securities	0	0
Derivatives	0	0
Liabilities:
Derivatives	0	0
Contingent consideration	40	34
Level 3 \| Recurring \| Money market funds
Assets:
Money market funds	$ 0	$ 0

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions			3 Months Ended
	Mar. 31, 2025	Apr. 01, 2024	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Business Acquisition [Line Items]
Cash consideration, net of cash acquired			$ 269	$ 0
Gain on remeasurement of NMP equity method investment			97	0
Goodwill	$ 13,373		13,373		$ 13,136
Amortization of acquisition-related intangible assets			70	$ 80
Nihon Medi-Physics
Business Acquisition [Line Items]
Defined benefit plan, asset	73		73
Defined benefit plan, liability	34		34
Defined benefit plan, net asset	$ 39		$ 39
Nihon Medi-Physics
Business Acquisition [Line Items]
Percent of interest acquired	50.00%		50.00%
Cash consideration, net of cash acquired	$ 269
Equity interest in acquiree, existing percentage	50.00%		50.00%
Fair value of previously held interest in NMP	$ 301
Equity interest in acquiree, carrying value	204
Gain on remeasurement of NMP equity method investment	97
Foreign currency translation gain, reclassification adjustment	63
Defined benefit pension plan loss, reclassification adjustment	8
Definite-lived intangible assets acquired	$ 200
Acquired finite-lived intangible assets, weighted average useful life	12 years
Asset retirement obligations and decommissioning liabilities assumed	$ 96		$ 96
Purchase price	575
Goodwill	216		216
Intangible assets	223		223
Deferred tax liabilities	87		$ 87
Nihon Medi-Physics \| IPR&D
Business Acquisition [Line Items]
Indefinite-lived intangible assets acquired	$ 23
MIM Software
Business Acquisition [Line Items]
Percent of interest acquired		100.00%
Cash consideration, net of cash acquired		$ 259
Cash acquired from acquisition		11
Purchase price		283
Goodwill		189
Deferred tax liabilities		13
Other net assets		7
MIM Software \| Customer-related
Business Acquisition [Line Items]
Intangible assets		52
MIM Software \| Developed technology
Business Acquisition [Line Items]
Intangible assets		48
MIM Software \| Purchase price
Business Acquisition [Line Items]
Contingent consideration		13
MIM Software \| Service requirements
Business Acquisition [Line Items]
Contingent consideration		$ 23

BORROWINGS - Narrative (Details)	3 Months Ended	12 Months Ended
BORROWINGS - Narrative (Details)	Mar. 31, 2025 USD ($) series	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
Principal debt issued	$ 8,780,000,000	$ 9,036,000,000
Guarantee obligation, carrying value	2,000,000	3,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure	786,000,000	784,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure	24,000,000	25,000,000
Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding	0	$ 0
Senior unsecured notes \| Senior notes
Debt Instrument [Line Items]
Debt, principal amount	$ 8,250,000,000
Number of debt series \| series	6
5-Year Revolving Credit Facility \| Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Debt, term	5 years	5 years
Maximum borrowing capacity	$ 3,000,000,000
364-Day Revolving Credit Facility \| Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Debt, term	364 days	364 days
Maximum borrowing capacity	$ 500,000,000
Floating rate Term Loan Facility due January 2, 2026 \| Line of credit
Debt Instrument [Line Items]
Principal debt issued	500,000,000	$ 750,000,000
Debt repayments	$ 250,000,000
Floating rate Term Loan Facility due January 2, 2026 \| Line of credit \| Unsecured debt
Debt Instrument [Line Items]
Debt, term	3 years
Maximum borrowing capacity	$ 2,000,000,000

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Business Acquisitions (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 31, 2025	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Purchase consideration
Cash consideration, net of cash acquired		$ 269	$ 0
Initial allocation
Goodwill	$ 13,373	13,373		$ 13,136
Nihon Medi-Physics
Purchase consideration
Cash consideration, net of cash acquired	269
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	575
Initial allocation
Receivables	53	53
Inventories	10	10
Property, plant, and equipment	243	243
Goodwill	216	216
Other intangible assets	223	223
All other non-current assets	52	52
Deferred income taxes	(87)	(87)
All other non-current liabilities	(107)	(107)
Other	(28)	(28)
Total net assets post acquisition	575	575
Indemnification assets	$ 12	$ 12

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Derivative [Line Items]
Cash flow hedge gain to be reclassified within 12 months	$ 14
Derivative, potential effect of rights of offset to assets and liabilities	55	$ 77
Cash, cash equivalents, and restricted cash	2,473	2,889
Estimated fair value
Derivative [Line Items]
Borrowings	9,223	9,374
Carrying value
Derivative [Line Items]
Borrowings	8,759	8,951
Money market funds \| Recurring
Derivative [Line Items]
Cash, cash equivalents, and restricted cash	230	312
Other cash equivalents \| Recurring
Derivative [Line Items]
Cash, cash equivalents, and restricted cash	$ 1,229	$ 1,573

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows - operating activities
Net income	$ 588	$ 388
Adjustments to reconcile Net income to Cash from (used for) operating activities
Depreciation of property, plant, and equipment	66	68
Amortization of intangible assets	70	80
Gain on remeasurement of Nihon Medi-Physics equity method investment	(97)	0
Net periodic postretirement benefit plan (income) expense	(70)	(90)
Postretirement plan contributions	(98)	(87)
Share-based compensation	22	34
Provision for income taxes	104	124
Cash paid during the year for income taxes	(91)	(86)
Changes in operating assets and liabilities, excluding the effects of acquisitions:
Receivables	81	165
Inventories	(154)	(59)
Contract and other deferred assets	52	32
Accounts payable	146	31
Contract liabilities	(68)	(18)
Current compensation and benefits	(200)	(34)
All other operating activities – net	(101)	(129)
Cash from (used for) operating activities	250	419
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(152)	(145)
Purchases of businesses, net of cash acquired	(269)	0
Purchases of investments	(20)	(19)
All other investing activities – net	34	(24)
Cash from (used for) investing activities	(407)	(188)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	1	1
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	0	1
Repayments and other reductions (maturities longer than 90 days)	(257)	(153)
Dividends paid to stockholders	(16)	(14)
Proceeds from stock issued under employee benefit plans	20	16
Taxes paid related to net share settlement of equity awards	(28)	(11)
All other financing activities – net	(6)	7
Cash from (used for) financing activities	(286)	(153)
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	27	(19)
Increase (decrease) in cash, cash equivalents, and restricted cash	(416)	59
Cash, cash equivalents, and restricted cash at beginning of year	2,893	2,506
Cash, cash equivalents, and restricted cash at end of period	2,476	2,565
Supplemental disclosure of cash flows information
Cash paid during the year for interest	(78)	(55)
Non-cash investing activities
Acquired but unpaid property, plant, and equipment	$ 86	$ 53

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

EARNINGS PER SHARE

The numerator for both basic and diluted earnings per share (“EPS”) is Net income attributable to GE HealthCare. The denominator of basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units, and performance share units is reflected in the denominator for diluted EPS using the treasury stock method.


Earnings Per Share	For the three months ended March 31
(In millions, except per share amounts)		2025		2024
Numerator:
Net income		$	588	$	388
Net (income) loss attributable to noncontrolling interests		(24)		(14)
Net income attributable to GE HealthCare		564		374


Denominator:
Basic weighted-average shares outstanding		457		456
Dilutive effect of common stock equivalents		2		3
Diluted weighted-average shares outstanding		459		459

Basic earnings per share		$	1.23	$	0.82



Diluted earnings per share		1.23		0.81


Antidilutive securities(1)		2		4

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Noncurrent Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract liabilities	$ 724	$ 686
Operating lease liabilities	266	270
Environmental and asset retirement obligations	395	291
Income and indirect tax liabilities including uncertain tax positions	170	237
Derivative instruments	39	64
Finance lease obligations	$ 40	$ 40
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	All other non-current liabilities	All other non-current liabilities
Sales allowances and related liabilities	$ 24	$ 23
Other	182	184
All other non-current liabilities	$ 1,840	$ 1,796

LEASES	3 Months Ended
LEASES	Mar. 31, 2025
Leases [Abstract]
LEASES	LEASES Operating lease liabilities recognized within All other current liabilities and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position were $386 million and $385 million as of March 31, 2025 and December 31, 2024, respectively. The total lease expense related to our operating lease portfolio was $62 million and $60 million for the three months ended March 31, 2025 and 2024, respectively.

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings” for further information.

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.



	For the three months ended March 31
	2025		2024
Balance at beginning of period	$	168	$	192
Current-year provisions	59		41
Expenditures	(58)		(55)
Foreign currency exchange and other	2		(2)
Balance at end of period	$	171	$	175

Product warranties are recognized within All other current liabilities in the Condensed Consolidated Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matters described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matters described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision. On June 24, 2024, the Supreme Court vacated the D.C. Circuit’s decision and remanded the case to the D.C. Circuit for further consideration. On November 19, 2024, the D.C. Circuit heard oral argument from the parties, and the D.C. Circuit’s decision is pending. The proceedings in the District Court are currently inactive.

Government Disclosures

From time to time, we make self-disclosures regarding our compliance with the Foreign Corrupt Practices Act (“FCPA”) and similar laws to relevant authorities who may pursue or decline to pursue enforcement proceedings against us. We, with the assistance of outside counsel, made voluntary self-disclosures to the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) beginning in 2018 regarding tender irregularities and other potential violations of the FCPA relating to our activities in certain provinces in China. We have been engaged in ongoing discussions with each of the SEC and the DOJ regarding these matters. We are fully cooperating with the reviews by these agencies and have implemented, and continue to implement, enhancements to our compliance policies and practices. At this time, we are unable to predict the duration, scope, result, or related costs associated with these disclosures to the SEC and the DOJ. We also are unable to predict what, if any, action may be taken by the SEC or the DOJ or what penalties or remedial actions they may seek. Any determination that our operations or activities are not in compliance with existing laws or regulations, including applicable foreign laws, could result in the imposition of fines, penalties, disgorgement, equitable relief, or other losses.

RESTRUCTURING ACTIVITIES - Schedule of Restructuring Activities (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 21	$ 25
Facility and other exit costs	0	8
Asset write-downs	1	7
Total restructuring activities – net	$ 22	$ 40

SEGMENT INFORMATION - Schedule of Segment EBIT (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
EBIT	$ 715	$ 681
Restructuring costs	(22)	(40)
Acquisition and disposition-related benefits (charges)	(8)	0
Gain (loss) on business and asset dispositions	10	0
Spin-Off and separation costs	(24)	(60)
Amortization of acquisition-related intangible assets	(35)	(31)
Investment revaluation gain (loss)	92	(20)
Interest and other financial charges – net	(110)	(122)
Non-operating benefit income (costs)	74	102
Income before income taxes	692	512
Operating segments \| Imaging
Segment Reporting Information [Line Items]
EBIT	199	166
Operating segments \| AVS
Segment Reporting Information [Line Items]
EBIT	261	257
Operating segments \| PCS
Segment Reporting Information [Line Items]
EBIT	48	81
Operating segments \| PDx
Segment Reporting Information [Line Items]
EBIT	205	178
Other
Segment Reporting Information [Line Items]
EBIT	$ 2	$ (1)